Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Modelling the MYC-driven normal-to-tumour switch in breast cancer.

Lourenco C, Kalkat M, Houlahan KE, De Melo J, Longo J, Done SJ, Boutros PC, Penn LZ.

Dis Model Mech. 2019 Jul 26;12(7). pii: dmm038083. doi: 10.1242/dmm.038083.

2.

Performance measures of magnetic resonance imaging plus mammography in the High Risk Ontario Breast Screening Program.

Chiarelli AM, Blackmore KM, Muradali D, Done SJ, Majpruz V, Weerasinghe A, Mirea L, Eisen A, Rabeneck L, Warner E.

J Natl Cancer Inst. 2019 Jun 24. pii: djz079. doi: 10.1093/jnci/djz079. [Epub ahead of print]

PMID:
31233143
3.

Annual versus biennial screening: diagnostic accuracy among concurrent cohorts within the Ontario Breast Screening Program.

Chiarelli AM, Blackmore KM, Mirea L, Done SJ, Majpruz V, Weerasinghe A, Rabeneck L, Muradali D.

J Natl Cancer Inst. 2019 Jun 24. pii: djz131. doi: 10.1093/jnci/djz131. [Epub ahead of print]

PMID:
31233138
4.

Breast specimen handling and reporting in the post-neoadjuvant setting: challenges and advances.

Mrkonjic M, Berman HK, Done SJ, Youngson B, Mulligan AM.

J Clin Pathol. 2019 Feb;72(2):120-132. doi: 10.1136/jclinpath-2018-205598. Review.

PMID:
30670564
5.

MYC Protein Interactome Profiling Reveals Functionally Distinct Regions that Cooperate to Drive Tumorigenesis.

Kalkat M, Resetca D, Lourenco C, Chan PK, Wei Y, Shiah YJ, Vitkin N, Tong Y, Sunnerhagen M, Done SJ, Boutros PC, Raught B, Penn LZ.

Mol Cell. 2018 Dec 6;72(5):836-848.e7. doi: 10.1016/j.molcel.2018.09.031. Epub 2018 Nov 8.

PMID:
30415952
6.

Cdh1 and Pik3ca Mutations Cooperate to Induce Immune-Related Invasive Lobular Carcinoma of the Breast.

An Y, Adams JR, Hollern DP, Zhao A, Chang SG, Gams MS, Chung PED, He X, Jangra R, Shah JS, Yang J, Beck LA, Raghuram N, Kozma KJ, Loch AJ, Wang W, Fan C, Done SJ, Zacksenhaus E, Guidos CJ, Perou CM, Egan SE.

Cell Rep. 2018 Oct 16;25(3):702-714.e6. doi: 10.1016/j.celrep.2018.09.056.

7.

Breast tumour resembling tall cell variant of papillary thyroid carcinoma: case presentation (in a patient with Lynch syndrome).

Gai L, Done SJ, Cook D, Denic N, Erivwo P, Voisey K, Kao K.

J Clin Pathol. 2018 Nov;71(11):1031-1032. doi: 10.1136/jclinpath-2018-205337. Epub 2018 Jul 7. No abstract available.

PMID:
29982234
8.

Mapping genomic and transcriptomic alterations spatially in epithelial cells adjacent to human breast carcinoma.

Abdalla M, Tran-Thanh D, Moreno J, Iakovlev V, Nair R, Kanwar N, Abdalla M, Lee JPY, Kwan JYY, Cawthorn TR, Warren K, Arneson N, Wang DY, Fox NS, Youngson BJ, Miller NA, Easson AM, McCready D, Leong WL, Boutros PC, Done SJ.

Nat Commun. 2017 Nov 1;8(1):1245. doi: 10.1038/s41467-017-01357-y.

9.

Negative Enrichment and Isolation of Circulating Tumor Cells for Whole Genome Amplification.

Kanwar N, Done SJ.

Methods Mol Biol. 2017;1634:143-152. doi: 10.1007/978-1-4939-7144-2_11.

PMID:
28819847
10.

Omitting radiation therapy after lumpectomy for pure DCIS does not reduce the risk of salvage mastectomy.

Rakovitch E, Nofech-Mozes S, Hanna W, Sutradhar R, Gu S, Fong C, Tuck A, Youngson B, Miller N, Done SJ, Chang MC, Sengupta S, Elavathil L, Jani PA, Bonin M, Lalani N, Paszat L.

Breast. 2018 Feb;37:181-186. doi: 10.1016/j.breast.2017.07.002. Epub 2017 Aug 3.

PMID:
28781102
11.

Molecular Profiling and Significance of Circulating Tumor Cell Based Genetic Signatures.

Kanwar N, Done SJ.

Adv Exp Med Biol. 2017;994:143-167. doi: 10.1007/978-3-319-55947-6_8. Review.

PMID:
28560673
12.

Changes of collagen ultrastructure in breast cancer tissue determined by second-harmonic generation double Stokes-Mueller polarimetric microscopy.

Golaraei A, Kontenis L, Cisek R, Tokarz D, Done SJ, Wilson BC, Barzda V.

Biomed Opt Express. 2016 Sep 15;7(10):4054-4068. eCollection 2016 Oct 1.

13.

Digital versus screen-film mammography: impact of mammographic density and hormone therapy on breast cancer detection.

Chiarelli AM, Prummel MV, Muradali D, Shumak RS, Majpruz V, Brown P, Jiang H, Done SJ, Yaffe MJ.

Breast Cancer Res Treat. 2015 Nov;154(2):377-87. doi: 10.1007/s10549-015-3622-x. Epub 2015 Oct 30.

PMID:
26518019
14.

Ras Signaling Is a Key Determinant for Metastatic Dissemination and Poor Survival of Luminal Breast Cancer Patients.

Wright KL, Adams JR, Liu JC, Loch AJ, Wong RG, Jo CE, Beck LA, Santhanam DR, Weiss L, Mei X, Lane TF, Koralov SB, Done SJ, Woodgett JR, Zacksenhaus E, Hu P, Egan SE.

Cancer Res. 2015 Nov 15;75(22):4960-72. doi: 10.1158/0008-5472.CAN-14-2992. Epub 2015 Sep 23.

15.

Digital Compared with Screen-Film Mammography: Measures of Diagnostic Accuracy among Women Screened in the Ontario Breast Screening Program.

Prummel MV, Muradali D, Shumak R, Majpruz V, Brown P, Jiang H, Done SJ, Yaffe MJ, Chiarelli AM.

Radiology. 2016 Feb;278(2):365-73. doi: 10.1148/radiol.2015150733. Epub 2015 Sep 2.

PMID:
26334680
16.

Close or positive resection margins are not associated with an increased risk of chest wall recurrence in women with DCIS treated by mastectomy: a population-based analysis.

Klein J, Kong I, Paszat L, Nofech-Mozes S, Hanna W, Thiruchelvam D, Narod SA, Saskin R, Done SJ, Miller N, Youngson B, Tuck A, Sengupta S, Elavathil L, Jani PA, Slodkowska E, Bonin M, Rakovitch E.

Springerplus. 2015 Jul 10;4:335. doi: 10.1186/s40064-015-1032-5. eCollection 2015.

17.

Identification of a Low-Risk Luminal A Breast Cancer Cohort That May Not Benefit From Breast Radiotherapy.

Liu FF, Shi W, Done SJ, Miller N, Pintilie M, Voduc D, Nielsen TO, Nofech-Mozes S, Chang MC, Whelan TJ, Weir LM, Olivotto IA, McCready DR, Fyles AW.

J Clin Oncol. 2015 Jun 20;33(18):2035-40. doi: 10.1200/JCO.2014.57.7999. Epub 2015 May 11.

PMID:
25964246
18.

Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study.

Dowling RJ, Niraula S, Chang MC, Done SJ, Ennis M, McCready DR, Leong WL, Escallon JM, Reedijk M, Goodwin PJ, Stambolic V.

Breast Cancer Res. 2015 Mar 3;17:32. doi: 10.1186/s13058-015-0540-0.

19.

Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial.

Hadad SM, Coates P, Jordan LB, Dowling RJ, Chang MC, Done SJ, Purdie CA, Goodwin PJ, Stambolic V, Moulder-Thompson S, Thompson AM.

Breast Cancer Res Treat. 2015 Feb;150(1):149-55. doi: 10.1007/s10549-015-3307-5. Epub 2015 Feb 15.

PMID:
25682077
20.

Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression.

Harris IS, Treloar AE, Inoue S, Sasaki M, Gorrini C, Lee KC, Yung KY, Brenner D, Knobbe-Thomsen CB, Cox MA, Elia A, Berger T, Cescon DW, Adeoye A, Brüstle A, Molyneux SD, Mason JM, Li WY, Yamamoto K, Wakeham A, Berman HK, Khokha R, Done SJ, Kavanagh TJ, Lam CW, Mak TW.

Cancer Cell. 2015 Feb 9;27(2):211-22. doi: 10.1016/j.ccell.2014.11.019. Epub 2015 Jan 22. Erratum in: Cancer Cell. 2015 Feb 9;27(2):314.

21.

Identification of genomic signatures in circulating tumor cells from breast cancer.

Kanwar N, Hu P, Bedard P, Clemons M, McCready D, Done SJ.

Int J Cancer. 2015 Jul 15;137(2):332-44. doi: 10.1002/ijc.29399. Epub 2015 Jan 12.

22.

B7-H4 expression by nonhematopoietic cells in the tumor microenvironment promotes antitumor immunity.

Rahbar R, Lin A, Ghazarian M, Yau HL, Paramathas S, Lang PA, Schildknecht A, Elford AR, Garcia-Batres C, Martin B, Berman HK, Leong WL, McCready DR, Reedijk M, Done SJ, Miller N, Youngson B, Suh WK, Mak TW, Ohashi PS.

Cancer Immunol Res. 2015 Feb;3(2):184-95. doi: 10.1158/2326-6066.CIR-14-0113. Epub 2014 Dec 19.

23.
24.

Long-term outcomes of hypofractionation versus conventional radiation therapy after breast-conserving surgery for ductal carcinoma in situ of the breast.

Lalani N, Paszat L, Sutradhar R, Thiruchelvam D, Nofech-Mozes S, Hanna W, Slodkowska E, Done SJ, Miller N, Youngson B, Tuck A, Sengupta S, Elavathil L, Chang MC, Jani PA, Bonin M, Rakovitch E.

Int J Radiat Oncol Biol Phys. 2014 Dec 1;90(5):1017-24. doi: 10.1016/j.ijrobp.2014.07.026. Epub 2014 Sep 11.

PMID:
25220719
25.

Digital compared to screen-film mammography: breast cancer prognostic features in an organized screening program.

Prummel MV, Done SJ, Muradali D, Majpruz V, Brown P, Jiang H, Shumak RS, Yaffe MJ, Holloway CM, Chiarelli AM.

Breast Cancer Res Treat. 2014 Sep;147(2):389-99. doi: 10.1007/s10549-014-3088-2. Epub 2014 Aug 10.

PMID:
25108740
26.
27.

Age at diagnosis predicts local recurrence in women treated with breast-conserving surgery and postoperative radiation therapy for ductal carcinoma in situ: a population-based outcomes analysis.

Kong I, Narod SA, Taylor C, Paszat L, Saskin R, Nofech-Moses S, Thiruchelvam D, Hanna W, Pignol JP, Sengupta S, Elavathil L, Jani PA, Done SJ, Metcalfe S, Rakovitch E.

Curr Oncol. 2014 Feb;21(1):e96-e104. doi: 10.3747/co.21.1604.

28.

Role of Nek2 on centrosome duplication and aneuploidy in breast cancer cells.

Cappello P, Blaser H, Gorrini C, Lin DC, Elia AJ, Wakeham A, Haider S, Boutros PC, Mason JM, Miller NA, Youngson B, Done SJ, Mak TW.

Oncogene. 2014 May 1;33(18):2375-84. doi: 10.1038/onc.2013.183. Epub 2013 May 27.

29.

Impact of boost radiation in the treatment of ductal carcinoma in situ: a population-based analysis.

Rakovitch E, Narod SA, Nofech-Moses S, Hanna W, Thiruchelvam D, Saskin R, Taylor C, Tuck A, Youngson B, Miller N, Done SJ, Sengupta S, Elavathil L, Jani PA, Bonin M, Metcalfe S, Paszat L.

Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):491-7. doi: 10.1016/j.ijrobp.2013.02.031.

PMID:
23708085
30.

Digital compared with screen-film mammography: performance measures in concurrent cohorts within an organized breast screening program.

Chiarelli AM, Edwards SA, Prummel MV, Muradali D, Majpruz V, Done SJ, Brown P, Shumak RS, Yaffe MJ.

Radiology. 2013 Sep;268(3):684-93. doi: 10.1148/radiol.13122567. Epub 2013 May 14.

PMID:
23674784
31.

Can we select individuals with low risk ductal carcinoma in situ (DCIS)? A population-based outcomes analysis.

Rakovitch E, Nofech-Mozes S, Narod SA, Hanna W, Thiruchelvam D, Saskin R, Taylor C, Tuck A, Sengupta S, Elavathil L, Jani PA, Done SJ, Miller N, Youngson B, Kong I, Paszat L.

Breast Cancer Res Treat. 2013 Apr;138(2):581-90. doi: 10.1007/s10549-013-2455-8. Epub 2013 Mar 3.

PMID:
23456231
32.

Incidence of breast cancer in patients with pure flat epithelial atypia diagnosed at core-needle biopsy of the breast.

Khoumais NA, Scaranelo AM, Moshonov H, Kulkarni SR, Miller N, McCready DR, Youngson BJ, Crystal P, Done SJ.

Ann Surg Oncol. 2013 Jan;20(1):133-8. doi: 10.1245/s10434-012-2591-0. Epub 2012 Oct 12.

PMID:
23064777
33.

Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study.

Niraula S, Dowling RJ, Ennis M, Chang MC, Done SJ, Hood N, Escallon J, Leong WL, McCready DR, Reedijk M, Stambolic V, Goodwin PJ.

Breast Cancer Res Treat. 2012 Oct;135(3):821-30. doi: 10.1007/s10549-012-2223-1. Epub 2012 Aug 30.

PMID:
22933030
34.

Embryonic protein nodal promotes breast cancer vascularization.

Quail DF, Walsh LA, Zhang G, Findlay SD, Moreno J, Fung L, Ablack A, Lewis JD, Done SJ, Hess DA, Postovit LM.

Cancer Res. 2012 Aug 1;72(15):3851-63.

35.

¹¹¹In-Bn-DTPA-nimotuzumab with/without modification with nuclear translocation sequence (NLS) peptides: an Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-resistant breast cancer.

Fasih A, Fonge H, Cai Z, Leyton JV, Tikhomirov I, Done SJ, Reilly RM.

Breast Cancer Res Treat. 2012 Aug;135(1):189-200. doi: 10.1007/s10549-012-2137-y. Epub 2012 Jun 27.

PMID:
22736376
36.

Role of antibody-mediated tumor targeting and route of administration in nanoparticle tumor accumulation in vivo.

Chattopadhyay N, Fonge H, Cai Z, Scollard D, Lechtman E, Done SJ, Pignol JP, Reilly RM.

Mol Pharm. 2012 Aug 6;9(8):2168-79. doi: 10.1021/mp300016p. Epub 2012 Jul 18.

PMID:
22734589
37.

Comparison of whole genome amplification methods for analysis of DNA extracted from microdissected early breast lesions in formalin-fixed paraffin-embedded tissue.

Arneson N, Moreno J, Iakovlev V, Ghazani A, Warren K, McCready D, Jurisica I, Done SJ.

ISRN Oncol. 2012;2012:710692. doi: 10.5402/2012/710692. Epub 2012 Mar 14.

38.

Mitochondrial D310 mutations in the early development of breast cancer.

Xu C, Tran-Thanh D, Ma C, May K, Jung J, Vecchiarelli J, Done SJ.

Br J Cancer. 2012 Apr 24;106(9):1506-11. doi: 10.1038/bjc.2012.74.

39.

Proteomic analyses reveal high expression of decorin and endoplasmin (HSP90B1) are associated with breast cancer metastasis and decreased survival.

Cawthorn TR, Moreno JC, Dharsee M, Tran-Thanh D, Ackloo S, Zhu PH, Sardana G, Chen J, Kupchak P, Jacks LM, Miller NA, Youngson BJ, Iakovlev V, Guidos CJ, Vallis KA, Evans KR, McCready D, Leong WL, Done SJ.

PLoS One. 2012;7(2):e30992. doi: 10.1371/journal.pone.0030992. Epub 2012 Feb 20.

40.

A new gene expression signature, the ClinicoMolecular Triad Classification, may improve prediction and prognostication of breast cancer at the time of diagnosis.

Wang DY, Done SJ, McCready DR, Boerner S, Kulkarni S, Leong WL.

Breast Cancer Res. 2011 Sep 22;13(5):R92. doi: 10.1186/bcr3017.

41.

Clinical relevance of DNA microarray analyses using archival formalin-fixed paraffin-embedded breast cancer specimens.

Sadi AM, Wang DY, Youngson BJ, Miller N, Boerner S, Done SJ, Leong WL.

BMC Cancer. 2011 Jun 16;11:253:1-13. doi: 10.1186/1471-2407-11-25.

42.

Acquisition of metastatic tissue from patients with bone metastases from breast cancer.

Hilton JF, Amir E, Hopkins S, Nabavi M, DiPrimio G, Sheikh A, Done SJ, Gianfelice D, Kanji F, Dent S, Barth D, Bouganim N, Al-Najjar A, Clemons M.

Breast Cancer Res Treat. 2011 Oct;129(3):761-5. doi: 10.1007/s10549-010-1264-6. Epub 2010 Nov 27.

PMID:
21113656
43.

Expression of Abl interactor 1 and its prognostic significance in breast cancer: a tissue-array-based investigation.

Wang C, Tran-Thanh D, Moreno JC, Cawthorn TR, Jacks LM, Wang DY, McCready DR, Done SJ.

Breast Cancer Res Treat. 2011 Sep;129(2):373-86. doi: 10.1007/s10549-010-1241-0. Epub 2010 Nov 3.

PMID:
21046228
44.

Amplification of the prolactin receptor gene in mammary lobular neoplasia.

Tran-Thanh D, Arneson NC, Pintilie M, Deliallisi A, Warren KS, Bane A, Done SJ.

Breast Cancer Res Treat. 2011 Jul;128(1):31-40. doi: 10.1007/s10549-010-1025-6. Epub 2010 Jul 24.

PMID:
20658264
45.

Troglitazone suppresses telomerase activity independently of PPARgamma in estrogen-receptor negative breast cancer cells.

Rashid-Kolvear F, Taboski MA, Nguyen J, Wang DY, Harrington LA, Done SJ.

BMC Cancer. 2010 Jul 22;10:390. doi: 10.1186/1471-2407-10-390.

46.

Antitumor effects and normal-tissue toxicity of 111In-nuclear localization sequence-trastuzumab in athymic mice bearing HER-positive human breast cancer xenografts.

Costantini DL, McLarty K, Lee H, Done SJ, Vallis KA, Reilly RM.

J Nucl Med. 2010 Jul;51(7):1084-91. doi: 10.2967/jnumed.109.072389. Epub 2010 Jun 16.

47.

Local control with conventional and hypofractionated adjuvant radiotherapy after breast-conserving surgery for ductal carcinoma in-situ.

Williamson D, Dinniwell R, Fung S, Pintilie M, Done SJ, Fyles AW.

Radiother Oncol. 2010 Jun;95(3):317-20. doi: 10.1016/j.radonc.2010.03.021. Epub 2010 Apr 17.

PMID:
20400190
48.

Cyclooxygenase-2 inhibition for the prophylaxis and treatment of preinvasive breast cancer in a her-2/neu mouse model.

Tran-Thanh D, Buttars S, Wen Y, Wilson C, Done SJ.

Cancer Prev Res (Phila). 2010 Feb;3(2):202-11. doi: 10.1158/1940-6207.CAPR-09-0181. Epub 2010 Jan 26.

49.

The role of stromal factors in breast tumorigenicity.

Tran-Thanh D, Done SJ.

Am J Pathol. 2010 Mar;176(3):1072-4. doi: 10.2353/ajpath.2010.091128. Epub 2010 Jan 21. No abstract available.

50.

18F-FDG small-animal PET/CT differentiates trastuzumab-responsive from unresponsive human breast cancer xenografts in athymic mice.

McLarty K, Fasih A, Scollard DA, Done SJ, Vines DC, Green DE, Costantini DL, Reilly RM.

J Nucl Med. 2009 Nov;50(11):1848-56. doi: 10.2967/jnumed.109.067231. Epub 2009 Oct 16.

Supplemental Content

Support Center